Medication info
Sidipom Tablets 50/850 mg

Sidipom Tablets 50/850 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300855 · Approved 2023.03.13 · Insurance code 645907380

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient’s current metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient’s blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Studies evaluating the safety and efficacy of switching patients previously treated with other oral glucose-lowering drugs to this medicine have not been conducted. Any change in the treatment regimen for type 2 diabetes may result in changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used to improve blood sugar control in patients with type 2 diabetes along with diet and exercise. The components sitagliptin and metformin work together to effectively lower blood sugar levels. This combination therapy enhances blood sugar management and has a positive effect on diabetes treatment.

How to take

Adult dose

The dose of this medicine for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient’s current metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient’s blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Studies evaluating the safety and efficacy of switching patients previously treated with other oral glucose-lowering drugs to this medicine have not been conducted. Any change in the treatment regimen for type 2 diabetes may result in changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).

Precautions

This medication contains sitagliptin and metformin and is used for the treatment of type 2 diabetes. Firstly, serious allergic reactions may occur during the use of this medication, so if symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck occur, stopping the medication immediately and consulting a physician is necessary. Additionally, acute pancreatitis may occur, so if sudden severe abdominal pain, nausea, vomiting, or fever occurs, seeking medical attention promptly is essential. Metformin, one of the components, can lead to rare but fatal lactic acidosis, so it should not be used in patients with poor kidney function, dehydration, severe infections, heart failure, or liver diseases. Patients with moderate to severe renal impairment or certain acute conditions should avoid this medication, and treatment should be stopped before and after examinations using radiologic contrast agents. It is not advised for women who are pregnant or may become pregnant, or for breastfeeding women. While taking this medication, it is essential to maintain regular meals and proper exercise, and blood glucose levels should be checked frequently as hypoglycemia may occur. The risk of hypoglycemia can be increased, especially when used in conjunction with insulin or other hypoglycemic agents. Moreover, this medication contains certain colorants, so caution is advised if there is an allergy to these components. In cases of surgery, severe infections, trauma, etc., taking this medication should be temporarily discontinued, and it should be resumed only after the patient’s condition stabilizes and kidney function returns to normal. During the use of this medication, it is advisable to avoid alcohol consumption, and kidney function and vitamin B12 levels should be regularly monitored for any abnormalities. Finally, it is important that patients taking this medication or their guardians fully understand the medication's effects and side effects, and report any unusual symptoms to healthcare professionals immediately.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 23 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • blistering pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dermatitis
  • loss of appetite
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • gastrointestinal disturbances
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air and moisture exposure, and it is best kept at room temperature between 1 degree and 30 degrees Celsius. Storing it this way will help maintain the effectiveness of the medication and prevent degradation.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.